Coiled reports £3.85 million interim loss after oncology transformation
Coiled Therapeutics ($COIL) reported a first-half loss before tax of £3.85 million, compared with £0.53 million a year earlier, following its shift into clinical-stage oncology. Operating activities consumed £2.85 million of cash versus £0.33 million previously. A financing completed during the period provided £7.78 million after fees, leaving cash of £5.10 million at the half-year close. The figures establish the funding position behind development of AO-252, its investigational TACC3 inhibitor
0